Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
GeoVax Labs announces updates on next generation COVID-19 vaccine » 08:08
05/24/23
05/24
08:08
05/24/23
08:08
GOVX

GeoVax Labs

/

+

GeoVax Labs announced the…

GeoVax Labs announced the presentation of updates on the development of its next-generation SARS-CoV-2 vaccine, GEO-CM04S1, including preliminary data from an ongoing Phase 2 clinical trial, during the Vaccines Summit Boston 2023 and the Congress for the International Society for the Advancement of Cytometry, CYTO, 2023 meetings. Each of the presentations included unpublished data from the open-label portion of the Phase 2 trial of CM04S1 in patients undergoing hematological cancer treatment. The preliminary analysis indicated CM04S1 is highly immunogenic in these patients, inducing both antibody responses, including neutralizing antibodies as well as T cell responses. Kelly McKee, M.D., GeoVax's Chief Medical Officer, commented, "These data extend to severely immunocompromised patients our earlier findings in healthy adults that GEO-CM04S1 stimulated a robust, durable, and broad-based humoral and cellular immune response against multiple SARS-CoV-2 variants. Validation of these findings in additional patients with hematologic malignancies, who have received CAR-T and stem cell transplants, is underway as we seek to provide a vaccine solution to those individuals unable to mount adequate protective responses with currently available COVID-19 vaccines."

ShowHide Related Items >><<
GOVX GeoVax Labs
/

+

GOVX GeoVax Labs
/

+

05/08/23 Noble Capital
GeoVax Labs initiated with an Outperform at Noble Capital
03/03/23 Dawson James
GeoVax Labs initiated with a Buy at Dawson James
10/26/22 H.C. Wainwright
GeoVax Labs initiated with a Buy at H.C. Wainwright
GOVX GeoVax Labs
/

+

GOVX GeoVax Labs
/

+

Over a week ago
Hot Stocks
GeoVax Labs to present vaccine data at upcoming scientific meetings » 09:27
05/15/23
05/15
09:27
05/15/23
09:27
GOVX

GeoVax Labs

/

+

GeoVax Labs announced…

GeoVax Labs announced that it will be represented during two upcoming scientific meetings, including Vaccines Summit Boston 2023 in Boston, MA, May 22-24, 2023 and CYTO 2023 in Montreal, Quebec, Canada, May 20-24, 2023. Don Diamond, Ph.D., Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, will deliver a presentation titled, "Assessment of GEO-CM04S1 for Prevention of COVID-19 in Immunocompromised Cell Therapy Patients; An Open-Label Safety Study." Dr. Diamond's presentation will include a description of the development and clinical testing of GeoVax's vaccine candidate, GEO-CM04S1. CM04S1 is a next-generation COVID-19 vaccine based on the use of the MVA viral vector platform, which presents multiple antigens to the immune system to induce both antibody and T cell responses. The vaccine is designed to provide durable protection against new and continually emerging variants of COVID-19, limiting the need for frequent modification and updating. GeoVax is focusing on the clinical development of this vaccine for use in patients with impaired ability to mount adequate protective immune responses to currently available COVID-19 vaccines, to include those with certain malignancies and autoimmune disorders, cell and organ transplant patients, individuals with end-stage kidney disease receiving hemodialysis, and potentially elderly individuals who respond poorly to other vaccines. These individuals may not be able to raise or maintain protective antibody responses following receipt of first-generation mRNA vaccines, contributing to reduced vaccine efficacy. On Tuesday, May 23, Sandra Ortega-Francisco, Ph.D., Department of Hematology and Hematopoietic Cell Transplantation and Hematologic Malignancies Research Institute, City of Hope, will participate in a poster presentation titled, "Induction of multi-antigen specific T cell responses by a synthetic MVA-SARS-CoV-2 vaccine in patients with hematological malignancies."

ShowHide Related Items >><<
GOVX GeoVax Labs
/

+

GOVX GeoVax Labs
/

+

05/08/23 Noble Capital
GeoVax Labs initiated with an Outperform at Noble Capital
03/03/23 Dawson James
GeoVax Labs initiated with a Buy at Dawson James
10/26/22 H.C. Wainwright
GeoVax Labs initiated with a Buy at H.C. Wainwright
05/23/22 Maxim
Maxim sees GeoVax Labs undervalued, citing its MVA vaccine in monkeypox
GOVX GeoVax Labs
/

+

GOVX GeoVax Labs
/

+

Initiation
GeoVax Labs initiated with an Outperform at Noble Capital » 08:18
05/08/23
05/08
08:18
05/08/23
08:18
GOVX

GeoVax Labs

/

+

Noble Capital initiated…

Noble Capital initiated coverage of GeoVax Labs with an Outperform rating and $6 price target. Gedeptin, its lead cancer product, is a gene-directed therapy for cancer that uses a proprietary delivery technology to deliver a gene to the cancer cells that converts an inactive prodrug into an active cytotoxic drug within the tumor cells, the analyst tells investors. The firm, which believes company fundamentals have been improving as the environment for small capitalization biotechnology company stocks has been in a long decline, expects the stock to be driven by the clinical milestones in development programs for Gedeptin and CM04S1, a next-generation COVID-19 vaccine.

ShowHide Related Items >><<
GOVX GeoVax Labs
/

+

GOVX GeoVax Labs
/

+

03/03/23 Dawson James
GeoVax Labs initiated with a Buy at Dawson James
10/26/22 H.C. Wainwright
GeoVax Labs initiated with a Buy at H.C. Wainwright
05/23/22 Maxim
Maxim sees GeoVax Labs undervalued, citing its MVA vaccine in monkeypox
GOVX GeoVax Labs
/

+

GOVX GeoVax Labs
/

+

Earnings
GeoVax Labs reports Q1 EPS (15c), consensus (20c) » 16:04
05/04/23
05/04
16:04
05/04/23
16:04
GOVX

GeoVax Labs

/

+

GeoVax reported cash…

GeoVax reported cash balances of $23,849,860 at March 31 as compared to $27,612,732 at December 31, last year a decrease of $3,762,872. David Dodd, GeoVax's Chairman and CEO, commented, "During the first quarter of 2023, our corporate focus continued to be on the advancement of our ongoing clinical trials for our Gedeptin cancer therapy targeting advanced head and neck cancers and CM04S1, our next-generation SARS-CoV-2 vaccine. Positive initial data was recently presented for CM04S1 during the World Vaccine Congress, and our Gedeptin trial has expanded to additional NCI-designated Cancer Centers, allowing us to accelerate our patient enrollment efforts; we look forward to completing enrollment for this trial in the very near future. I look forward to reporting further progress on each of our ongoing clinical trials during the remainder of the year." Dodd further commented, "In addition to clinical progress, the first quarter was filled with many notable achievements for GeoVax. Significant progress has been made in developing a high-yield, high-capacity, continuous avian cell line system for manufacturing our MVA-based vaccines and immunotherapies, such as CM04S1. We believe this will provide GeoVax the ability to respond to large-scale world needs in a timely manner. Additionally, the recent expansion of our CM04S1 rights to include development for Mpox and smallpox adds to other rights we previously secured from the NIH covering preclinical, clinical and commercial uses of the NIH-MVA, potentially adding significant value to our MVA-based vaccines under development."

ShowHide Related Items >><<
GOVX GeoVax Labs
/

+

GOVX GeoVax Labs
/

+

03/03/23 Dawson James
GeoVax Labs initiated with a Buy at Dawson James
10/26/22 H.C. Wainwright
GeoVax Labs initiated with a Buy at H.C. Wainwright
05/23/22 Maxim
Maxim sees GeoVax Labs undervalued, citing its MVA vaccine in monkeypox
GOVX GeoVax Labs
/

+

Over a month ago
Hot Stocks
GeoVax Labs announces expansion of next-generation vaccine rights » 09:14
04/17/23
04/17
09:14
04/17/23
09:14
GOVX

GeoVax Labs

/

+

GeoVax Labs announced the…

GeoVax Labs announced the expansion of its rights under its exclusive license agreement with City of Hope, COH, a world-renowned cancer research and treatment organization, to include development and commercialization rights against orthopoxviruses in addition to SARS-CoV-2. The original license agreement with COH provides GeoVax exclusive worldwide rights to key patents, including the use of COH's proprietary synthetic MVA process, for developing COVID-19 vaccines, including GEO-CM04S1, a multi-antigenic SARS-CoV-2 investigational vaccine expressing the spike and nucleocapsid antigens of the SARS-CoV-2 virus. CM04S1 is currently being studied in two ongoing Phase 2 clinical trials. The amendment to the license announced today grants GeoVax an expanded field of use to develop vaccine products, such as CM04S1, which target the prevention, reduction, amelioration or treatment of COVID-19 to also include targeting the prevention, reduction, amelioration or treatment of diseases caused by a virus within the orthopoxvirus genus. Orthopoxviruses include Mpox, smallpox, and other viruses that cause disease in humans.

ShowHide Related Items >><<
GOVX GeoVax Labs
/

+

GOVX GeoVax Labs
/

+

03/03/23 Dawson James
GeoVax Labs initiated with a Buy at Dawson James
10/26/22 H.C. Wainwright
GeoVax Labs initiated with a Buy at H.C. Wainwright
05/23/22 Maxim
Maxim sees GeoVax Labs undervalued, citing its MVA vaccine in monkeypox
GOVX GeoVax Labs
/

+

Hot Stocks
GeoVax announces presentation of preliminary data of Covid vaccine candidate » 10:02
04/06/23
04/06
10:02
04/06/23
10:02
GOVX

GeoVax Labs

/

+

GeoVax Labs presented an…

GeoVax Labs presented an update on the development of its SARS-CoV-2 vaccine, GEO-CM04S1, including preliminary data from an ongoing Phase 2 clinical trial, during the 23rd Annual World Vaccine Congress taking place in Washington, DC. The presentation, titled "COVID-19 Vaccine CM04S1; A Superior Viral Platform Alternative for Eliciting Durable T Cell Responses in Immunocompromised Hematologic Malignancy Patients," was delivered by Dr. Don Diamond, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope. Based on data from animal models and a completed Phase 1 clinical study, vaccine-induced immune responses were shown to recognize both early and later variants of SARS-CoV-2, including the Omicron variant. Vaccines of this format should not require repeated modification and updating. Diamond's presentation included unpublished data from the open-label portion of the Phase 2 trial of CM04S1 in patients undergoing hematological cancer treatment. The preliminary analysis indicates CM04S1 is highly immunogenic in these patients, inducing both antibody responses, including neutralizing antibodies, and T cell responses. These data support the planned progression of the Phase 2 clinical study, which will include a direct comparison to currently approved mRNA vaccines. CM04S1 continues to advance in a second Phase 2 clinical trial as a booster for healthy patients who have previously received the Pfizer or Moderna mRNA vaccine. Data from these studies will form the basis for comparing vaccine potential in unique patient groups as well as the general population, the company said.

ShowHide Related Items >><<
GOVX GeoVax Labs
/

+

GOVX GeoVax Labs
/

+

03/03/23 Dawson James
GeoVax Labs initiated with a Buy at Dawson James
10/26/22 H.C. Wainwright
GeoVax Labs initiated with a Buy at H.C. Wainwright
05/23/22 Maxim
Maxim sees GeoVax Labs undervalued, citing its MVA vaccine in monkeypox
GOVX GeoVax Labs
/

+

Hot Stocks
GeoVax Labs presents data from primate studies of Marburg vaccine candidate » 13:32
04/05/23
04/05
13:32
04/05/23
13:32
GOVX

GeoVax Labs

/

+

GeoVax Labs announced the…

GeoVax Labs announced the presentation of data from recent nonhuman primate studies of GeoVax's vaccine candidate against Marburg virus, during the 23rd Annual World Vaccine Congress taking place in Washington, DC. The data were presented by Dr. Jason Comer, Associate Professor, Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, in a presentation titled "Preclinical Capabilities at the University of Texas Medical Branch: Evaluating Candidate Vaccines and Immunotherapeutics against Sudan Ebola Virus," during the session on Emerging and Re-Emerging Diseases. Dr. Comer's presentation focused on UTMB's services for regulated, nonclinical studies, and included data from recent studies conducted on behalf of GeoVax. Following encouraging results showing complete protection from Marburg virus challenge in guinea pigs, GeoVax's vaccine efficacy studies targeting Marburg virus and Sudan Ebola virus disease were contracted to UTMB through the National Institute of Allergy and Infectious Disease Preclinical Services. Of particular interest, immunization with GeoVax's vaccine candidate conferred 80% survival in cynomolgus macaques following a lethal dose of Marburg virus. Vaccination protected nonhuman primates from viremia, weight loss and death following challenge with a lethal Marburg virus dose. Evaluation of immune responses following vaccination demonstrated the presence of both neutralizing antibodies and functional T cells, indicating a breadth of responses that combine for optimal protection. The work conducted by UTMB built upon earlier studies demonstrating that guinea pigs vaccinated with GEO-MM01 were 100% protected against death and disease caused by the Angola strain of Marburg virus. The vaccine induced immune responses were characterized by Marburg virus-specific binding and neutralizing antibodies as well as other effector functions like antibody-dependent phagocytosis. The Angola strain is the most virulent strain of Marburg Virus characterized by up to a 90% fatality rate in humans and a successful vaccination approach is of paramount public health importance.

ShowHide Related Items >><<
GOVX GeoVax Labs
/

+

GOVX GeoVax Labs
/

+

03/03/23 Dawson James
GeoVax Labs initiated with a Buy at Dawson James
10/26/22 H.C. Wainwright
GeoVax Labs initiated with a Buy at H.C. Wainwright
05/23/22 Maxim
Maxim sees GeoVax Labs undervalued, citing its MVA vaccine in monkeypox
GOVX GeoVax Labs
/

+

On The Fly
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 09:38
03/03/23
03/03
09:38
03/03/23
09:38
CDNA

CareDx

$10.77 /

-5.235 (-32.72%)

, STLA

Stellantis

$18.36 /

+0.1 (+0.55%)

, PG

Procter & Gamble

$139.90 /

+2.26 (+1.64%)

, RDNT

RadNet

$23.83 /

+0.52 (+2.23%)

, BILI

Bilibili

$21.56 /

+1.885 (+9.58%)

, ITRI

Itron

$56.73 /

+1.04 (+1.87%)

, DPZ

Domino's Pizza

$305.27 /

+3.755 (+1.25%)

, VNO

Vornado

$19.62 /

+0.035 (+0.18%)

, DEI

Douglas Emmett

$14.30 /

+0.13 (+0.92%)

, POAHY

Porsche

$5.73 /

+ (+0.00%)

, TTD

Trade Desk

$56.39 /

+1.005 (+1.81%)

, ELVN

Enliven

$23.69 /

+1.46 (+6.57%)

, GOVX

GeoVax Labs

/

+

, NXT

Nextracker

$31.86 /

+0.82 (+2.64%)

, TOWN

TowneBank

$29.87 /

-0.44 (-1.45%)

Want to get stock-moving…

ShowHide Related Items >><<
VNO Vornado
$19.62 /

+0.035 (+0.18%)

TTD Trade Desk
$56.39 /

+1.005 (+1.81%)

TOWN TowneBank
$29.87 /

-0.44 (-1.45%)

STLA Stellantis
$18.36 /

+0.1 (+0.55%)

RDNT RadNet
$23.83 /

+0.52 (+2.23%)

POAHY Porsche
$5.73 /

+ (+0.00%)

PG Procter & Gamble
$139.90 /

+2.26 (+1.64%)

ITRI Itron
$56.73 /

+1.04 (+1.87%)

GOVX GeoVax Labs
/

+

ELVN Enliven
$23.69 /

+1.46 (+6.57%)

DPZ Domino's Pizza
$305.27 /

+3.755 (+1.25%)

DEI Douglas Emmett
$14.30 /

+0.13 (+0.92%)

CDNA CareDx
$10.77 /

-5.235 (-32.72%)

BILI Bilibili
$21.56 /

+1.885 (+9.58%)

CDNA CareDx
$10.77 /

-5.235 (-32.72%)

03/03/23 Craig-Hallum
CareDx downgraded to Hold at Craig-Hallum after Medicare 'worst case scenario'
03/03/23 Craig-Hallum
CareDx downgraded to Hold from Buy at Craig-Hallum
03/03/23 Raymond James
CareDx double downgraded to Market Perform at Raymond James
03/03/23 Raymond James
CareDx downgraded to Market Perform from Strong Buy at Raymond James
STLA Stellantis
$18.36 /

+0.1 (+0.55%)

03/03/23 RBC Capital
Stellantis upgraded to Outperform from Sector Perform at RBC Capital
02/24/23 RBC Capital
Stellantis price target raised to EUR 19 from EUR 18 at RBC Capital
01/30/23 Berenberg
Stellantis price target lowered to EUR 18 from EUR 19 at Berenberg
01/25/23 Morgan Stanley
Stellantis price target lowered to EUR 18 from EUR 18.50 at Morgan Stanley
PG Procter & Gamble
$139.90 /

+2.26 (+1.64%)

03/03/23 JPMorgan
Procter & Gamble upgraded to Overweight from Neutral at JPMorgan
03/01/23 UBS
Procter & Gamble upgraded to Buy from Neutral at UBS
02/16/23 Citi
Citi launches beverage, personal space with six buys, two sells
02/16/23 Citi
Procter & Gamble initiated with a Buy at Citi
RDNT RadNet
$23.83 /

+0.52 (+2.23%)

03/03/23 Raymond James
RadNet upgraded to Outperform on AI visibility at Raymond James
03/03/23 Raymond James
RadNet upgraded to Outperform from Market Perform at Raymond James
09/29/22 Clarus
Biogen's lecanemab could be positive revenue driver for Akumin, says Clarus
BILI Bilibili
$21.56 /

+1.885 (+9.58%)

03/03/23 Citi
Bilibili upgraded to Buy at Citi with growth seen picking up
03/03/23 Citi
Bilibili upgraded to Buy from Neutral at Citi
12/13/22 Bernstein
Bilibili raised to Market Perform at Bernstein with short case 'less compelling'
12/13/22 Bernstein
Bilibili upgraded to Market Perform from Underperform at Bernstein
ITRI Itron
$56.73 /

+1.04 (+1.87%)

03/03/23 JPMorgan
Itron downgraded to Underweight from Neutral at JPMorgan
02/28/23 Piper Sandler
Itron price target raised to $58 from $48 at Piper Sandler
02/28/23 Baird
Itron price target raised to $52 from $40 at Baird
02/02/23 TD Cowen
Itron price target raised to $72 from $55 at Cowen
DPZ Domino's Pizza
$305.27 /

+3.755 (+1.25%)

03/03/23
Domino's Pizza downgraded at Gordon Haskett on lower long-term growth algorithm
03/03/23
Domino's Pizza downgraded to Hold from Buy at Gordon Haskett
02/28/23 Stifel
Domino's Pizza price target lowered to $300 from $320 at Stifel
02/28/23 Northcoast
Domino's Pizza downgraded to Neutral from Buy at Northcoast
VNO Vornado
$19.62 /

+0.035 (+0.18%)

03/03/23 BMO Capital
Vornado downgraded to Underperform from Market Perform at BMO Capital
01/04/23 Deutsche Bank
Vornado price target lowered to $22 from $25 at Deutsche Bank
01/04/23 Mizuho
Vornado upgraded to Neutral from Underperform at Mizuho
12/14/22 Citi
Vornado downgraded to Sell from Neutral at Citi
DEI Douglas Emmett
$14.30 /

+0.13 (+0.92%)

03/03/23 BMO Capital
Douglas Emmett downgraded to Underperform from Market Perform at BMO Capital
01/09/23 Credit Suisse
Douglas Emmett downgraded to Neutral from Outperform at Credit Suisse
01/03/23 Jefferies
Douglas Emmett downgraded at Jefferies on potential for worst case for offices
01/02/23 Jefferies
Douglas Emmett downgraded to Underperform from Hold at Jefferies
POAHY Porsche
$5.73 /

+ (+0.00%)

03/03/23 HSBC
Porsche downgraded to Hold from Buy at HSBC
01/30/23 Berenberg
Porsche price target raised to EUR 120 from EUR 96.80 at Berenberg
01/25/23 Morgan Stanley
Porsche price target raised to EUR 90 from EUR 82.50 at Morgan Stanley
01/11/23 Exane BNP Paribas
Porsche downgraded to Neutral from Outperform at Exane BNP Paribas
TTD Trade Desk
$56.39 /

+1.005 (+1.81%)

03/03/23 BTIG
Trade Desk initiated with a Neutral at BTIG
02/17/23 Citi
Trade Desk price target raised to $76 from $60 at Citi
02/16/23 Morgan Stanley
Trade Desk price target raised to $58 from $50 at Morgan Stanley
02/16/23 DA Davidson
Trade Desk price target raised to $76 from $56 at DA Davidson
ELVN Enliven
$23.69 /

+1.46 (+6.57%)

03/03/23 TD Cowen
Enliven initiated with an Outperform at TD Cowen
GOVX GeoVax Labs
/

+

03/03/23 Dawson James
GeoVax Labs initiated with a Buy at Dawson James
10/26/22 H.C. Wainwright
GeoVax Labs initiated with a Buy at H.C. Wainwright
05/23/22 Maxim
Maxim sees GeoVax Labs undervalued, citing its MVA vaccine in monkeypox
NXT Nextracker
$31.86 /

+0.82 (+2.64%)

03/03/23 Cantor Fitzgerald
Nextracker initiated with an Overweight at Cantor Fitzgerald
03/03/23 Cantor Fitzgerald
Nextracker initiated with an Overweight at Cantor Fitzgerald
TOWN TowneBank
$29.87 /

-0.44 (-1.45%)

03/03/23 Raymond James
TowneBank resumed with an Outperform at Raymond James
03/03/23 Raymond James
TowneBank initiated with an Outperform at Raymond James
02/17/23 Piper Sandler
TowneBank resumed with an Overweight at Piper Sandler
VNO Vornado
$19.62 /

+0.035 (+0.18%)

TTD Trade Desk
$56.39 /

+1.005 (+1.81%)

TOWN TowneBank
$29.87 /

-0.44 (-1.45%)

STLA Stellantis
$18.36 /

+0.1 (+0.55%)

RDNT RadNet
$23.83 /

+0.52 (+2.23%)

PG Procter & Gamble
$139.90 /

+2.26 (+1.64%)

ITRI Itron
$56.73 /

+1.04 (+1.87%)

DPZ Domino's Pizza
$305.27 /

+3.755 (+1.25%)

DEI Douglas Emmett
$14.30 /

+0.13 (+0.92%)

CDNA CareDx
$10.77 /

-5.235 (-32.72%)

BILI Bilibili
$21.56 /

+1.885 (+9.58%)

  • 09
    Feb
TTD Trade Desk
$56.39 /

+1.005 (+1.81%)

STLA Stellantis
$18.36 /

+0.1 (+0.55%)

POAHY Porsche
$5.73 /

+ (+0.00%)

PG Procter & Gamble
$139.90 /

+2.26 (+1.64%)

BILI Bilibili
$21.56 /

+1.885 (+9.58%)

TTD Trade Desk
$56.39 /

+1.005 (+1.81%)

STLA Stellantis
$18.36 /

+0.1 (+0.55%)

POAHY Porsche
$5.73 /

+ (+0.00%)

PG Procter & Gamble
$139.90 /

+2.26 (+1.64%)

NXT Nextracker
$31.86 /

+0.82 (+2.64%)

DPZ Domino's Pizza
$305.27 /

+3.755 (+1.25%)

DEI Douglas Emmett
$14.30 /

+0.13 (+0.92%)

CDNA CareDx
$10.77 /

-5.235 (-32.72%)

BILI Bilibili
$21.56 /

+1.885 (+9.58%)

VNO Vornado
$19.62 /

+0.035 (+0.18%)

TTD Trade Desk
$56.39 /

+1.005 (+1.81%)

STLA Stellantis
$18.36 /

+0.1 (+0.55%)

PG Procter & Gamble
$139.90 /

+2.26 (+1.64%)

ELVN Enliven
$23.69 /

+1.46 (+6.57%)

DPZ Domino's Pizza
$305.27 /

+3.755 (+1.25%)

BILI Bilibili
$21.56 /

+1.885 (+9.58%)

Initiation
GeoVax Labs initiated with a Buy at Dawson James » 07:46
03/03/23
03/03
07:46
03/03/23
07:46
GOVX

GeoVax Labs

/

+

Dawson James analyst…

Dawson James analyst Jason Kolbert initiated coverage of GeoVax Labs with a Buy rating and $4 price target. Under the leadership of David Dodd, GeoVax has "transformed itself" and now has "two assets that are worthy of attention," the analyst tells investors. Gedeptin, a gene therapy for solid tumors, is now in Phase 1/2 trials in advanced head and neck squamous cell carcinoma, or HNSCC, and GEO-CM02, a COVID-19 vaccine for immunocompromised patients, the firm said.

ShowHide Related Items >><<
GOVX GeoVax Labs
/

+

GOVX GeoVax Labs
/

+

10/26/22 H.C. Wainwright
GeoVax Labs initiated with a Buy at H.C. Wainwright
05/23/22 Maxim
Maxim sees GeoVax Labs undervalued, citing its MVA vaccine in monkeypox
Hot Stocks
GeoVax announces presentation of results from clinical study of HIV therapy » 09:06
02/27/23
02/27
09:06
02/27/23
09:06
GOVX

GeoVax Labs

/

+

GeoVax Labs announced the…

GeoVax Labs announced the presentation of results from a clinical study of a combinational HIV therapy that included GeoVax's HIV vaccine candidate, MVA62B. The data were presented at the Conference on Retroviruses and Opportunistic Infections held February 19-22, 2023, in Seattle, Washington. The data were generated, in a clinical trial led by researchers at the University of California, San Francisco, to develop a combinational therapy aimed at reducing or eliminating viral replication in the absence of antiviral medications in HIV-positive individuals. The primary objectives of the proof-of-concept trial were to assess the safety and tolerability of the combinational therapy and to determine the viral load "set-point" during antiviral treatment interruption. Secondary objectives were to assess immune responses and changes in viral reservoir status. The clinical trial was led by Steven Deeks, M.D. of UCSF, a world leader in therapeutic approaches to HIV infections, and was one of the most comprehensive tests to date for the ability of synergistic approaches to control HIV infection. The studies were conducted with funding from amfAR, The Foundation for AIDS Research.

ShowHide Related Items >><<
GOVX GeoVax Labs
/

+

GOVX GeoVax Labs
/

+

10/26/22 H.C. Wainwright
GeoVax Labs initiated with a Buy at H.C. Wainwright
05/23/22 Maxim
Maxim sees GeoVax Labs undervalued, citing its MVA vaccine in monkeypox

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.